| Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer. | |
| | |
MedLine Citation:
|
PMID: 22274315 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVE: Tumor-associated neoangiogenesis (TAN) is an early event in ovarian tumor development. Interleukin 16 (IL-16) is a proangiogenic cytokine that stimulates production of neoangiogenic factors. The goal of this study was to determine the association of IL-16 with tumor development and ovarian TAN in laying hens, an animal model of spontaneous ovarian cancer (OVCA). METHODS: Sera and ovarian tissues from 3-year-old laying hens were collected and processed for histopathologic, immunoassay, immunohistochemistry, immunoblotting, and molecular biological studies to determine the tissue expression and serum levels of IL-16. Samples were divided into 3 groups based on the diagnosis of the histopathologic ovarian tissue examination, namely, normal (healthy control, n = 81), early (n = 23 including 11 with microscopic OVCA), and late stages (n = 16) of OVCA. RESULTS: Serum levels of IL-16 were significantly higher in hens with microscopic, early, and late stages of OVCA than normal hens (P < 0.0001). The frequencies of IL-16cells in tumor-bearing ovaries were significantly higher than normal hens (P < 0.05). The expression of IL-16 protein and mRNA were stronger in tumor-bearing ovaries than normal ovaries. In addition to ovarian stroma, IL-16 was also expressed by the epithelial cells of the tumor in OVCA hens. Differences in serum levels and ovarian IL-16 expression were not significant among different histological subtypes of OVCA including serous, endometrioid, and mucinous. Similar to the serum levels and ovarian expression of IL-16, the densities of neoangiogenic microvessels were significantly higher in hens with tumor-bearing ovaries than normal hens. CONCLUSIONS: The results of the study suggest that changes in serum levels of IL-16 are associated with tumor development and TAN. Thus, serum IL-16 levels may be an indicator of ovarian TAN at the early stage of OVCA. |
| | |
Authors:
|
Aparna Yellapa; Janice M Bahr; Pincas Bitterman; Jacques S Abramowicz; Seby L Edassery; Krishna Penumatsa; Sanjib Basu; Jacob Rotmensch; Animesh Barua |
Related Documents
:
|
12641275 - Epstein-barr virus and undifferentiated nasopharyngeal carcinoma: new immunobiological ... 10794545 - Differential cell cycle response of nontumorigenic and tumorigenic human papillomavirus... 11314535 - Human papillomavirus infection and p53 alteration in oral squamous cell carcinoma. 8575855 - Malignant transformation of hpv 16-immortalized human endocervical cells by cigarette s... 18670825 - Flt-pet imaging of radiation responses in murine tumors. 8637045 - Suramin-induced decrease in prostate-specific antigen expression with no effect on tumo... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society Volume: 22 ISSN: 1525-1438 ISO Abbreviation: Int. J. Gynecol. Cancer Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9111626 Medline TA: Int J Gynecol Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 199-207 Citation Subset: IM |
Affiliation:
|
*Department of Pharmacology, Rush University Medical Center, Chicago; †Department of Animal Sciences, University of Illinois at Urbana-Champaign; and Departments of ‡Pathology, §Obstetrics and Gynecology, and ∥Preventive Medicine (Biostatistics), Rush University Medical Center, Chicago, IL. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian...
Next Document: Frequent Loss of Tumor Suppressor ARID1A Protein Expression in Adenocarcinomas/Adenosquamous Carcino...